Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KCd for relapsed or refractory POEMS syndrome
ChiCTR2600133388Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of carfilzomib, cyclophosphamide and dexamethasone in osteosclerotic myeloma (POEMS), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective response rate. Started Jan 2026; status: recruiting.
02
Drugs
carfilzomibcyclophosphamidedexamethasone
03
Conditions
osteosclerotic myeloma (POEMS)
Beyond the preview
Go deeper on ChiCTR2600133388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133388.